From Targeted Oncology
TAC01-HER2, an autologous TAC-T cell lead asset made to target HER2 in relapsed or refractory gastric and gastroesophageal junction tumors, is being further evaluated in phase 2 of the TACTIC-2 study.
The first patient with relapsed or refractory HER2-positive gastric and gastroesophageal junction (GEJ) tumors has been dosed with TAC01-HER2 in phase 2 of the phase 1/2 TACTIC-2 (NCT04727151) study.1
TAC01-HER2 is an autologous TAC-T cell lead asset being developed to target HER2 in relapsed or refractory gastric and GEJ tumors. The novel cell therapy is based on genetically engineered autologous T cells expressing a T-cell antigen coupler which recognizes HER2.
